EFTR
Effector Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
940
P/E Ratio
—
EPS
$-12.57
Beta
0.89
52W High
$0.00
52W Low
$0.00
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Effector Therapeutics Inc
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company focused on pioneering targeted cancer therapies through the selective modulation of RNA translation. By innovatively altering protein synthesis within tumor cells, the company aims to address significant unmet needs in oncology with its portfolio of small molecule treatments. With a diverse pipeline of product candidates under development, Effector Therapeutics is committed to advancing precision medicine, striving to enhance treatment outcomes and quality of life for cancer patients in a rapidly evolving biotechnology environment.
Fundamentals
| Revenue (TTM) | 675,000 |
| Gross Profit (TTM) | $-21.62M |
| EBITDA | $-32.59M |
| Operating Margin | 0.00% |
| Return on Equity | -947.00% |
| Return on Assets | -83.30% |
| Revenue/Share (TTM) | $0.35 |
| Book Value | $0.21 |
| Price-to-Book | 0.00 |
| Price-to-Sales (TTM) | 69.65 |
| EV/Revenue | - |
| EV/EBITDA | -0.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 117.00% |
| Shares Outstanding | $4.70M |
| Float | $4.67M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
More HEALTHCARE Stocks
Data last updated: 5/2/2026